KRYS Share Price Performance
US$0
-134.94 (-100.00%)
Price US$0
Fair ValueUS$361.67
Share Pricen/a
Seeking Alpha • Jul 29
Krystal Biotech, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 72 Fair Values set on narratives written by author
KRYS Community Narratives
AN
Fair Value
·Fair Value US$361.67 5.7% undervalued intrinsic discount
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
AN
Fair Value
·Fair Value US$371 8.1% undervalued intrinsic discount
Aging Populations And AI Will Accelerate Gene Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$241 41.5% overvalued intrinsic discount
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Krystal Biotech is trying to turn a single successful treatment into a broader global business, with launches in Europe and Japan and several new programs moving through testing. The upside is bigger reach and better efficiency, but uneven patient use, reimbursement hurdles, and fast-moving competition could quickly slow the story.Read more
AN
US$361.67
5.7% undervalued intrinsic discount
Fair Value
Revenue
34.77% p.a.
Profit Margin
54.06%
Future PE
24.95x
Price in 2029
US$442.25
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
Krystal Biotech’s skin gene therapy is spreading into more countries, but patient stop-and-start treatment and tougher pricing talks could make sales swing around and squeeze profits. With new programs depending on upcoming trial results and more rivals entering gene therapy, the next few years could bring either a wider runway or a bumpier ride than many expect.Read more
AN
US$241
41.5% overvalued intrinsic discount
Fair Value
Revenue
25.06% p.a.
Profit Margin
38.66%
Future PE
29.14x
Price in 2029
US$295.18
Aging Populations And AI Will Accelerate Gene Therapy Adoption
Key Takeaways Rapid market penetration and strong operational scalability for VYJUVEK are expected to substantially increase revenue, margins, and earnings power beyond current analyst expectations. Robust pipeline progress, first-mover advantages, and AI-driven patient engagement initiatives could unlock multiple high-margin revenue streams and greater long-term growth.Read more
AN
US$371
8.1% undervalued intrinsic discount
Fair Value
Revenue
52.68% p.a.
Profit Margin
68.39%
Future PE
14.4x
Price in 2029
US$450.97
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
KRYS: Future Returns Will Weigh UK Approval Against 2026 Ophthalmology And CF Data
Fair Value: US$361.67 5.7% undervalued intrinsic discount
30 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Ophthalmology Readouts And KB707 Lung Data Will Test Pipeline Expectations
Fair Value: US$241 41.5% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Future CF And Ophthalmology Readouts Will Drive Long Term Upside
Fair Value: US$371 8.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Krystal Biotech, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 03, 2026
- 7.63
- 94.17%
- 53.92%
- 0%
About KRYS
- Founded
- 2016
- Employees
- 295
- CEO
- WebsiteView website
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Recent KRYS News & Updates
Narrative Update • Jul 22
